Innovating.works Conecta tu I+D

Mostrando 1 al 20 de 24 resultados

KAREVO: How dividing cells adapt to karyotypic evolution I3S INSTITUTO DE INVESTIGACAO E INOVACAO EM SAUDE DA UNIVERSIDADE DO PORTO tramitó un HORIZON EUROPE: ERC-2023-ADG Alterations in chromosome number and size are hallmarks of cancer, and yet they are also crucial for species evolution. Recent insight on ch...
2024-09-16 - 2029-12-31 | Financiado

MENTORING: Addressing malnutrition and metabolic health in non communicable diseases through precision Nutritio... Malnutrition represents a major burden for a large part of the population and, in particular, for vulnerable population groups like lung can...
2024-05-31 - 2028-08-31 | Financiado

D-PhosMate: Dynamic Peptide-Phosphate-based Hydrogels for Modelling Diseases and Therapeutic Interventions I3S INSTITUTO DE INVESTIGACAO E INOVACAO EM SAUDE DA UNIVERSIDADE DO PORTO tramitó un HORIZON EUROPE: HORIZON-MSCA-2023-PF-01 Supramolecular biomaterials represent a promising solution to address complex challenges in advanced therapies and disease modelling platfor...
2024-03-01 - 2026-05-31 | Financiado

AI4LUNGS: AI-BASED PERSONALISED CARE FOR RESPIRATORY DISEASE USING MULTI-MODAL DATA IN PATIENT STRATIFICATION I3S INSTITUTO DE INVESTIGACAO E INOVACAO EM SAUDE DA UNIVERSIDADE DO PORTO participó en un HORIZON EUROPE: HORIZON-HLTH-2022-TOOL-12-two-stage AI4Lungs will develop and validate novel AI-based tools and computational models to improve patient stratification optimising diagnosis and...
2023-12-07 - 2027-06-30 | Financiado

Blood2Power: Blood as energy source to power smart cardiac devices I3S INSTITUTO DE INVESTIGACAO E INOVACAO EM SAUDE DA UNIVERSIDADE DO PORTO tramitó un HORIZON EUROPE: HORIZON-EIC-2022-PATHFINDERCHALLENGES-01 Cardiovascular diseases (CVD) are the leading cause of death globally, taking 18.6M lives/yr. Most CVD are associated with blockage ofblood...
2023-10-01 - 2026-09-30 | Financiado

BonePainIII: Identifying mechanisms and novel treatments of bone pain – closing the gap to the clinic. I3S INSTITUTO DE INVESTIGACAO E INOVACAO EM SAUDE DA UNIVERSIDADE DO PORTO participó en un HORIZON EUROPE: HORIZON-MSCA-2022-DN-01 Musculoskeletal pain from diseases such as arthritis and cancer in the bone affects the quality of life of millions and is a major societal...
2023-07-14 - 2027-12-31 | Financiado

SkinModelOma: Multicompartment combinatory pre-clinical model for melanoma drug screening I3S INSTITUTO DE INVESTIGACAO E INOVACAO EM SAUDE DA UNIVERSIDADE DO PORTO tramitó un HORIZON EUROPE: HORIZON-WIDERA-2022-TALENTS-04 One of the biggest limitations in developing new treatments for cutaneous melanoma relies on overcoming the inefficient screening, often t...
2023-05-10 - 2025-05-31 | Financiado

TRAIN: Tumor Regulation Assisted by Immunity and Nanotechnology I3S INSTITUTO DE INVESTIGACAO E INOVACAO EM SAUDE DA UNIVERSIDADE DO PORTO tramitó un HORIZON EUROPE: HORIZON-MSCA-2022-PF-01 Cancer is the number one cause of death among Europeans under 65, being estimated that half of Europeans will develop cancer at some time in...
2023-03-30 - 2025-05-31 | Financiado

GlycanTrigger: GLYCANS AS MASTER TRIGGERS OF HEALTH TO INTESTINAL INFLAMMATION TRANSITION I3S INSTITUTO DE INVESTIGACAO E INOVACAO EM SAUDE DA UNIVERSIDADE DO PORTO tramitó un HORIZON EUROPE: HORIZON-HLTH-2022-STAYHLTH-02 Chronic inflammation underlies several diseases. In Crohn´s disease (CD), there is mounting evidence of a preclinical phase characterized by...
2023-01-01 - 2028-12-31 | Financiado

PREVENTABLE: CANCER PREVENTION VS CANCER TREATMENT: THE RARE TUMOUR RISK SYNDROMES BATTLE I3S INSTITUTO DE INVESTIGACAO E INOVACAO EM SAUDE DA UNIVERSIDADE DO PORTO tramitó un HORIZON EUROPE: HORIZON-HLTH-2022-CARE-08 Rare tumour risk syndromes (RTRS) are rare diseases, affecting 5 per 10.000 people or less and caused by heritable genetic variants. In RTRS...
2022-12-02 - 2025-12-31 | Financiado

REBORN: REMODELLING OF THE INFARCTED HEART: PIEZOELECTRIC MULTIFUNCTIONAL PATCH ENABLING THE SEQUENTIAL RELE... I3S INSTITUTO DE INVESTIGACAO E INOVACAO EM SAUDE DA UNIVERSIDADE DO PORTO participó en un HORIZON EUROPE: HORIZON-CL4-2022-RESILIENCE-01 Cardiac disease remains a major societal and healthcare burden that affect nearly two million European citizens every year. The REBORN proje...
2022-11-29 - 2026-12-31 | Financiado

PhotoSynH2: Photosynthetic electron focusing technology for direct efficient biohydrogen production from solar e... I3S INSTITUTO DE INVESTIGACAO E INOVACAO EM SAUDE DA UNIVERSIDADE DO PORTO participó en un HORIZON EUROPE: HORIZON-EIC-2021-PATHFINDERCHALLENGES-01 We propose a disruptive technology based on synthetic biology, we call photosynthetic electron focusing, for the efficient production of hyd...
2022-07-08 - 2027-09-30 | Financiado

SINPAIN: A game changer for the treatment of osteoarthritis: a cost effective combined advanced therapy to tr... I3S INSTITUTO DE INVESTIGACAO E INOVACAO EM SAUDE DA UNIVERSIDADE DO PORTO participó en un HORIZON EUROPE: HORIZON-HLTH-2021-TOOL-06 According to the WHO Osteoarthritis (OA) is one major course of years lived with disability in the elderly and considered a high burden dise...
2022-05-19 - 2026-10-31 | Financiado

GENEGUT: Oral delivery of encapsulated RNA nanotherapeutics for targeted treatment of ileal Crohn's disease I3S INSTITUTO DE INVESTIGACAO E INOVACAO EM SAUDE DA UNIVERSIDADE DO PORTO participó en un HORIZON EUROPE: HORIZON-HLTH-2021-TOOL-06 Crohn’s disease is a non-communicable, global disease with an accelerating incidence (up to 23 per 100,000 persons/year) and annual health c...
2022-05-19 - 2026-09-30 | Financiado

NEUROSENSE: NEUROendocrine SENSor for Sudden Unexpected Death in Epilepsy (SUDEP) prediction and prevention I3S INSTITUTO DE INVESTIGACAO E INOVACAO EM SAUDE DA UNIVERSIDADE DO PORTO tramitó un HORIZON EUROPE: HORIZON-EIC-2021-PATHFINDEROPEN-01 NEUROSENSE proposes a novel and visionary technology resulting from the demonstration of the upstream role of arousal in the sudden unexpect...
2022-04-13 - 2026-05-31 | Financiado

I3S INSTITUTO DE INVESTIGACAO E INOVACA...